Instant Alert: Shire's angioedema drug succeeds in late-stage study

MANAGE SUBSCRIPTIONS   |   UNSUBSCRIBE   |   VIEW ONLINE   Shire's angioedema drug succeeds in late-stage study by on May 18, 2017, 7:16 AM (Reuters) - Shire Plc said on Thursday its drug for hereditary angioedema (HAE), a disorder characterized by recurrent episodes of severe swelling, was successful in a late-stage study. The drug, lanadelumab, is being developed to prevent angioedema attacks. It was tested against a placebo over 26 weeks in patients 12 years of age or older with the rare genetic disease. (Reporting by Natalie Grover in Bengaluru; Editing by Martina D'Couto)   Share the latest business news with your network:    Email sent to:   |   Manage your email preferences   |   Unsubscribe Terms of Service   |   Privacy Policy Business Insider. 150 Fifth Avenue, New York, NY 10011